Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Annayyaon Mar 29, 2021 5:01pm
118 Views
Post# 32900396

RE:RE:RE:RE:RE:Shares

RE:RE:RE:RE:RE:SharesUnderstood, and I get your point now. I am not rich enough to participate in the PP or else I would definitely be interested in getting cheap 12 cent shares and 20 cent warrants with the 60 cent clause. It is the management's responsibility to move the company in the right direction so they don't have to do the PPs at such low prices. Seems like the outlook is good going forward with the almost 9 million CAD investment, and the upcoming news so we won't have to worry about extremely cheap PP in the future. I know you were holding all your shares when this went to 10 cents and below, and yes it was a very hard thing to do for us especially at a time when most of the stock market was going up. 

M101 wrote: Cashless exercise has nothing to do with the offering and it doesn't matter if it is used or not, the effect is the same. You could use margin or a bridge loan or whatever, the point is you only need the money for a few hours or days before you can sell the resulting shares and pocket the >200% profit on the borrowed amount. Obviously there will be many money lenders willing to help you do that for a fee, but assuming Goldstein's banker's main client is actually a money lender to start with that is irrelevant.  Everyone gets a cut in this scam, a cut that comes from yet more dilution only this time at 1/3 or worse of a market price which has been holding for over 2 months.
Had the terms been exercise at 50 cents if the warrants hold 60 cents then I would have agreed with you, but at 20 cents it's just another kick in the crotch.   
 




 
 


<< Previous
Bullboard Posts
Next >>